M Hanefeld

29.1k total citations · 6 hit papers
308 papers, 18.6k citations indexed

About

M Hanefeld is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, M Hanefeld has authored 308 papers receiving a total of 18.6k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Endocrinology, Diabetes and Metabolism, 88 papers in Molecular Biology and 64 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in M Hanefeld's work include Diabetes Treatment and Management (105 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (98 papers) and Metabolism, Diabetes, and Cancer (70 papers). M Hanefeld is often cited by papers focused on Diabetes Treatment and Management (105 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (98 papers) and Metabolism, Diabetes, and Cancer (70 papers). M Hanefeld collaborates with scholars based in Germany, United States and United Kingdom. M Hanefeld's co-authors include Ramón Gomis, Markku Laakso, Jean‐Louis Chiasson, Avraham Karasik, Theodora Temelkova‐Kurktschiev, Robert G. Josse, Carsta Koehler, Elena Henkel, Henning Beck‐Nielsen and Nigel C. Jones and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

M Hanefeld

294 papers receiving 17.4k citations

Hit Papers

Acarbose for prevention of type 2 diabetes mellitus: the ... 1996 2026 2006 2016 2002 2003 2006 2009 1996 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
    2002 1.8k citations Jean‐Louis Chiasson, Robert G. Josse et al. profile →
  2. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance
    2003 1.2k citations Jean‐Louis Chiasson, M Hanefeld et al. profile →
  3. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
    2006 1.2k citations Hertzel C. Gerstein, M Hanefeld et al. profile →
  4. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    2009 1.0k citations M Hanefeld et al. profile →
  5. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up
    1996 708 citations M Hanefeld, Ulrich Julius et al. Diabetologia profile →
  6. Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
    2007 561 citations M Hanefeld et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Hanefeld Germany 63 12.8k 6.1k 3.3k 2.7k 2.7k 308 18.6k
Alain Baron United States 45 8.0k 0.6× 3.8k 0.6× 3.8k 1.2× 2.1k 0.8× 3.1k 1.1× 70 13.7k
Michel Marre France 66 8.7k 0.7× 3.9k 0.6× 3.3k 1.0× 3.8k 1.4× 2.3k 0.8× 423 17.2k
Ramón Gomis Spain 47 8.6k 0.7× 3.8k 0.6× 3.1k 0.9× 3.9k 1.4× 1.9k 0.7× 174 14.8k
Giorgio Sesti Italy 67 6.9k 0.5× 5.6k 0.9× 3.4k 1.0× 2.7k 1.0× 2.8k 1.0× 416 15.1k
Itamar Raz Israel 67 15.2k 1.2× 6.1k 1.0× 5.6k 1.7× 6.4k 2.3× 3.3k 1.2× 374 26.0k
Katherine R. Tuttle United States 62 8.6k 0.7× 3.7k 0.6× 3.6k 1.1× 3.4k 1.2× 2.1k 0.8× 306 19.9k
Masakazu Haneda Japan 67 5.4k 0.4× 4.8k 0.8× 2.7k 0.8× 2.4k 0.9× 2.3k 0.8× 292 16.1k
Robert E. Ratner United States 60 10.7k 0.8× 3.7k 0.6× 5.1k 1.6× 2.0k 0.7× 1.8k 0.7× 159 16.6k
Alan J. Garber United States 51 9.1k 0.7× 3.9k 0.6× 3.8k 1.1× 1.1k 0.4× 2.1k 0.8× 142 13.3k
Clifford J. Bailey United Kingdom 67 12.3k 1.0× 8.2k 1.3× 5.4k 1.6× 876 0.3× 3.1k 1.2× 337 20.6k

Countries citing papers authored by M Hanefeld

Since Specialization
Citations

This map shows the geographic impact of M Hanefeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Hanefeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Hanefeld more than expected).

Fields of papers citing papers by M Hanefeld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Hanefeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Hanefeld. The network helps show where M Hanefeld may publish in the future.

Co-authorship network of co-authors of M Hanefeld

This figure shows the co-authorship network connecting the top 25 collaborators of M Hanefeld. A scholar is included among the top collaborators of M Hanefeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Hanefeld. M Hanefeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pistrosch, Frank & M Hanefeld. (2015). Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies. Current Diabetes Reports. 15(12). 117–117. 10 indexed citations
3.
Hanefeld, M, et al.. (2013). Predictors of Response to Early Basal Insulin Treatment in Patients with Type 2 Diabetes—The EARLY Experience. Diabetes Technology & Therapeutics. 16(4). 241–246. 15 indexed citations
4.
Bolli, Geremia B., Mihnea Munteanu, Elisabeth Niemoeller, et al.. (2013). Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1). Diabetic Medicine. 31(2). 176–184. 122 indexed citations
5.
Thomas, Andreas, et al.. (2009). The “Glucose Pentagon”: Assessing Glycemic Control of Patients with Diabetes Mellitus by a Model Integrating Different Parameters from Glucose Profiles. Diabetes Technology & Therapeutics. 11(6). 399–409. 27 indexed citations
6.
7.
Ott, P, et al.. (2009). „Diabetes in Germany” (DIG)-Studie. DMW - Deutsche Medizinische Wochenschrift. 134(7). 291–297. 16 indexed citations
8.
Mohler, Emile R., Christie M. Ballantyne, Michael H. Davidson, et al.. (2008). The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. Journal of the American College of Cardiology. 51(17). 1632–1641. 163 indexed citations
9.
Hanefeld, M, Nikolaus Marx, Andreas Pfützner, et al.. (2007). Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein. Journal of the American College of Cardiology. 49(3). 290–297. 141 indexed citations
10.
Hanefeld, M. (2007). Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. International Journal of Clinical Practice. 61(153). 20–27. 41 indexed citations
11.
Hanefeld, M & Frank Schäper. (2004). Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis. Herz. 29(5). 480. 2 indexed citations
12.
Hanefeld, M & Theodora Temelkova‐Kurktschiev. (2002). Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications.. PubMed. 12(2). 98–107. 67 indexed citations
13.
14.
Fritsch, Holger, et al.. (1997). [Postmenopausal hormone substitution and its effects on the climacteric syndrome, body weight and blood pressure].. PubMed. 119(3). 128–32. 3 indexed citations
15.
Hanefeld, M, et al.. (1994). The effect of UV irradiation on lipid levels and other serum parameters and on the circulation. Der Hautarzt. 5 indexed citations
16.
Julius, Ulrich, W. Leonhardt, Helen Schneider, et al.. (1979). Basal and stimulated hyperinsulinemia in obesity: relationship to adipose-cell size.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 73(2). 214–20. 5 indexed citations
17.
Haller, Hans, W. Leonhardt, M Hanefeld, & Ulrich Julius. (1979). Relationship between adipocyte hypertrophy and metabolic disturbances.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 74(1). 63–72. 14 indexed citations
18.
Leonhardt, W., M Hanefeld, Ulrich Julius, & Hans Haller. (1977). [Significance of fatty tissue hypertrophy for the metabolic risk].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 32(12). suppl 186–7. 1 indexed citations
19.
Gunther, W. C., W. Leonhardt, M Hanefeld, & Hermann Haller. (1977). Relation of lipoprotein lipase activity in adipose tissue to adipocyte volume and its influence in hypertriglyceridemia pathogenesis.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 70(2). 176–81. 1 indexed citations
20.
Haller, Hans, et al.. (1967). [Statistical studies on the pathogenesis of the fatty liver in diabetics].. PubMed. 22(2). 41–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alain Baron Breakdown of academic impact, for papers by Michel Marre Breakdown of academic impact, for papers by Ramón Gomis Breakdown of academic impact, for papers by Giorgio Sesti Breakdown of academic impact, for papers by Itamar Raz Breakdown of academic impact, for papers by Katherine R. Tuttle Breakdown of academic impact, for papers by Masakazu Haneda Breakdown of academic impact, for papers by Robert E. Ratner Breakdown of academic impact, for papers by Alan J. Garber Breakdown of academic impact, for papers by Clifford J. Bailey
Rankless by CCL
2026